Key result
Cangrelor provides moderate platelet inhibition during PCI, but switching to oral agents links to ~38% transient HRPR.
Why the study?
Pharmacodynamic investigations of cangrelor across various clinical settings and assays have yielded contrasting data regarding the extent of platelet inhibition and rates of high residual platelet reactivity.
Does cangrelor infusion and subsequent switch to oral P2Y12 inhibitors provide adequate platelet inhibition in patients undergoing PCI?
Observational (n=150)
Does cangrelor infusion and subsequent switch to oral P2Y12 inhibitors provide adequate platelet inhibition in patients undergoing PCI?
Switching from cangrelor to oral P2Y12 inhibitors, particularly clopidogrel, exposes a significant proportion of patients to high residual platelet reactivity in the hours following PCI.
May expose PCI patients to transient high residual platelet reactivity when switching from cangrelor to oral agents; leaves open optimal transition strategies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gargiulo et al. (2025) conducted an observational in Acute or chronic coronary syndrome undergoing percutaneous coronary intervention (n=150). Cangrelor was evaluated on Pharmacodynamic effects (inhibition of platelet aggregation and high residual platelet reactivity). Cangrelor infusion during PCI provided moderate platelet inhibition with 3.2% high residual platelet reactivity, though switching to oral inhibitors caused transient HRPR in up to 37.9% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: